Skip to main content
Equibles
TRVI logo

TRVI · Trevi Therapeutics, Inc. · Metrics

Track TRVI — free

Use TRVI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRVI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.94 +0.17 (+1.33%) At close · Oct 22
Russell 2000 member Rebalance outlook locked
Market Cap
$1.85B
Shares
142.48M
Volume · Oct 22 1.18M Avg daily vol (3M) 1.97M

TRVI metrics

63 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.94
Market cap
$1.85B

Price action

20 metrics
Price change (1W)
+6.9%
Price change (30D)
-15.1%
Price change (3M)
-24.7%
Price change (6M)
-8.8%
Price change (YTD)
+3.4%
Price change (1Y)
+18.8%
Trailing year
Price change (5Y)
+960.7%
52-week high
$19.50
52-week low
$9.99
Change from 52-week high
-33.6%
Change from 52-week low
+29.5%
Annualized volatility
57.7%
Annualized volatility (3M)
38.1%
Beta
1.2
RSI (14D)
40.2
Price vs SMA 50
-15.6%
Price vs SMA 200
-9.4%
Avg volume (3M)
1.97M
Relative volume
0.6
Average dollar volume
$30.27M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
142.48M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.7
reciprocal yield 17.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$59.56M
Net income (TTM)
−$51.11M
Trailing 12 months
Diluted EPS (TTM)
$-0.34
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.40
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.34
Operating cash flow per diluted share (TTM)
$-0.35
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.28
Stock compensation per diluted share (TTM)
$0.05
Book value per share
$1.43

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+20.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-15.9%
Return on assets
-15.5%
Debt / equity
0.0
Current ratio
37.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
37.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$318.87M
Latest balance sheet
Cash & equivalents
$54.30M
Total assets
$330.52M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$52.63M
Capital expenditures (TTM)
$238,000
R&D (TTM)
$41.37M
SG&A (TTM)
—
Stock compensation (TTM)
$8.06M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
221
13F filer change QoQ
+20
Institutional ownership
105.6%
Conviction holders (share of 13F filers)
5.5%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+10.0%
Holder tenure
10.3
Price vs estimated holder cost
+113.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.6%

Short interest

3 metrics
Short interest
10.3%
Latest settlement · 8.3 days to cover
Days to cover
8.3d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$595,806
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1563880 CUSIP 89532M101 13F (30d) 18 filings 18 filers Visit website Investor relations